An Alternative Purification Method for Human Serum Paraoxonase 1 and its Interactions with Sulfonamides

Chemical Biology and Drug Design

Volumn 76, Issue 6, 2010, Pages 552-558

  Ekinci, Deniz ^a,b   Şentürk, Murat ^a,c   Beydemir, Şükrü ^a   Irfan Küfrevioǧlu, Ömar ^a   Supuran, Claudiu T ^d  

^a ATATÜRK UNIVERSITY   (Turkey)

^b ONDOKUZ MAYIS UNIVERSITY   (Turkey)

^c AGRI IBRAHIM CECEN UNIVERSITY   (Turkey)

^d UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Drug target; Enzyme purification; Inhibition; Paraoxonase; Sulfonamides

Indexed keywords

1,3,4 THIADIAZOLE 2 SULFONAMIDE; ACETAZOLAMIDE; ARYLDIALKYLPHOSPHATASE 1; FUROSEMIDE; MAFENIDE; SALAZOSULFAPYRIDINE; SEPHADEX; SEPHAROSE; SULFACETAMIDE; SULFONAMIDE; UNCLASSIFIED DRUG;

ANION EXCHANGE CHROMATOGRAPHY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PURIFICATION; HUMAN; HYDROPHOBIC INTERACTION CHROMATOGRAPHY; IN VITRO STUDY; LETTER; PRIORITY JOURNAL;

ARYLDIALKYLPHOSPHATASE; CHEMISTRY TECHNIQUES, ANALYTICAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MOLECULAR STRUCTURE; SULFONAMIDES;

EID: 78349254260     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2010.01036.x     Document Type: Letter

References (53)

1. Harel M., Aharoni A., Gaidukov L., Brumshtein B., Khersonski O., Meged R., Dvir H., Ravelli R.B.G., McCarthy A., Toker L., Silman I., Sussman J.L., Tawkik D.S. (2004) Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol;11:412-419.
2. Lu H., Zhu J., Zang Y., Ze Y., Qin J. (2006) Cloning, purification, and refolding of human paraoxonase-3 expressed in Escherichia coli and its characterization. Protein Expr Purif;46:92-99.
3. Durringhton P.N., Mackness B., Mackness M.J. (2001) Paraoxonase and atherosclerosis. Arterioscler Thromb;21:473-480.
4. Primo-Parma S.L., Sorenson R.S., Teiber J., La Du B.N. (1996) The human serum paraoxonase/arylesterase gen (PON1) is one member of a multigene family. Genomics;33:498-509.
5. La Du B.N., Aviram M., Billecke S., Navab M., Primo-Parma S., Sorenson R.C., Standiford T.J. (1999) On the physiological role(s) of the paraoxonases. Chem Biol Interact;120:379-388.
6. Supuran C.T. (2008) Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov;7:168-181.
7. Mackness M.I., Arrol S., Durrington P.N. (1991) Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett;286:152-154.
8. Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Faull K.F., Fogelman A.M., Navab M. (1995) Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest;96:2882-2891.
9. Draganov D.I., La Du B. (2004) Pharmacogenetics of paraoxonases: a brief review. Naunyn Schmiedebergs Arch Pharmacol;369:78-88.
10. Ekinci D., Beydemir S. (2009) Evaluation of the impacts of antibiotic drugs on PON 1; a major bioscavenger against cardiovascular diseases. Eur J Pharmacol;617:84-89.
11. Ekinci D., Beydemir S. (2010) Purficication of PON 1 from human serum and assessment of enzyme kinetics against metal toxicity. Biol Trace Elem Res;135:112-120.
12. NTI Country Overviews:NTI Country Overviews: South Africa: Chemical Capabilities: Paraoxon.
13. Rodrigo L., Gil F., Hernandez A.F., Marina A., Vázquez J., Pla A. (1997) Purification and characterization of paraoxon hydrolase from rat liver. Biochem J;321:595-601.
14. Furlong C.E., Costa L.G., Hasett C., Richter R.J., Sundstrom J.A., Adler D.A., Disteche C.M., Omiecinski C.J., Crabb J.W., Humbert R. (1993) Human and rabbit paraoxonases: purification, cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification. Chem Biol Interact;87:35-48.
15. Pla A., Rodrigo L., Hernandez A.F., Gil F., Lopez O. (2007) Effect of metal ions and calcium on purified PON1 and PON3 from rat liver. Chem Biol Interact;167:63-70.
16. Sinan S., Kockar F., Arslan O. (2006) Novel purification strategy for human PON1 and inhibition of the activity by cephalosporin and aminoglycoside derived antibiotics. Biochimie;88:565-574.
17. Alici H.A., Ekinci D., Beydemir S. (2008) Intravenous anesthetics inhibit human Paraoxonase-I (PON1) activity in vitro and in vivo. Clin Biochem;41:1384-1390.
18. Gan K.N., Smolen A., Eckerson H.W., La Du B.N. (1991) Purification of the first 2 hr of incubation, after 6 hr, PON1-AA HDL retained human serum paraoxonase/arylesterase. Drug Metab Dispos;19:100-106.
19. Bayrak T., Bayrak A., Demirpençe E., Kilinç K. (2010) Purification and kinetic properties of rabbit liver paraoxonase 1. J Chromatogr B;878:1791-1795.
20. Draganov D.I., Stetson P.L., Watson C.E., Billecke S.S., LaDu B.N. (2000) Rabbit Serum Paraoxonase 3 (PON3) Is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem;275:33435-33442.
21. Rodrigoa L., Hernández A.F., López-Caballero J.J., Gila F., Pla A. (2001) Immunohistochemical evidence for the expression and induction of paraoxonase in rat liver, kidney, lung and brain tissue. implications for its physiological role. Chem Biol Interact;137:123-137.
22. Drew J. (2000) Drug discovery: a historical perspective. Science;287:1960-1964.
23. Supuran C.T., Scozzafava A., Casini A. (2003) Carbonic anhydrase inhibitors. Med Res Rev;23:146-189.
24. Supuran C.T., Casini A., Scozzafava A. (2003) Protease inhibitors of the sulfonamide type: anticancer, antiinflammatory, and antiviral agents. Med Res Rev;23:535-558.
25. Supuran C.T., Scozzafava A., Clare B.W. (2002) Bacterial protease inhibitors. Med Res Rev;22:329-372.
26. Supuran C.T., Scozzafava A. (2001) Carbonic anhydrase inhibitors. Curr Med Chem Immunol Endocr Metab Agents;1:61-97.
27. Supuran C.T. (2008) Carbonic anhydrases - an overview. Curr Pharm Des;14:603-614.
28. Supuran C.T., Conroy C.W., Maren T.H. (1996) Carbonic anhydrase inhibitors. Synthesis and inhibitory properties of 1, 3, 4-thiadiazole-2, 5-bissulfonamide. Eur J Med Chem;31:843-846.
29. Mastrolorenzo A., Rusconi S., Scozzafava A., Barbaro G., Supuran C.T. (2007) Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors. Curr Med Chem;14:2734-2748.
30. Supuran C.T., Scozzafava A. (2002) Applications of carbonic anhydrase inhibitors and activators in therapy. Expert Opin Ther Pat;12:217-242.
31. Sinan S. (2008) In vitro inhibition of the paraoxonase from human serum with sulfonamide. Afr J Biotechnol;7:508-512.
32. Bulbul M., Hisar O., Beydemir S., Ciftci M., Kufrevioglu O.I. (2003) The in vitro and in vivo inhibitory effects of some sulfonamide derivatives on Rainbow trout (Oncorhynchus mykiss) erythrocyte carbonic anhydrase activity. J Enzyme Inhib Med Chem;18:371-375.
33. Mincione F., Scozzafava A., Supuran C.T. (2009) Antiglaucoma carbonic anhydrase inhibitors as ophthalomologic drugs. In: Supuran C.T., Winum J.Y., editors. Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications. Hoboken: Wiley; p. 139-154.
34. Renault F., Chabrière E., Andrieu J.P., Dublet B., Masson P., Rochu D. (2006) Tandem purification of two HDL-associated partner proteins in human plasma, paraoxonase (PON1) and phosphate binding protein (HPBP) using hydroxyapatite chromatography. J Chromatogr B;836:15-21.
35. Ekinci D., Beydemir S. (2009) Effect of some analgesics on paraoxonase-1 purified from human serum. J Enzyme Inhib Med Chem;24:1034-1039.
36. Ekinci D., Senturk M., Beydemir S., Kufrevioglu O.I. (2008) An alternative method for purifying human serum paraoxonase-1. IV. National affinity techniques congress, 4-7 May 2008, p 61.
37. Bradford M.M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem;72:248-251.
38. Coban T.A., Beydemir S., Gulcin I., Ekinci D. (2007) Morphine inhibits erythrocyte carbonic anhydrase in vitro and in vivo. Biol Pharm Bull;30:2257-2261.
39. Laemmli D.K. (1970) Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature;227:680-683.
40. Lineweaver H., Burk D. (1934) The determination of enzyme dissociation constants. J Am Chem Soc;56:658-666.
41. Senturk M., Talaz O., Ekinci D., Cavdar H., Kufrevioglu O.I. (2009) In Vitro inhibition of human erythrocyte glutathione reductase by some new organic nitrates. Bioorg Med Chem Lett;19:3661-3663.
42. Mackness M.I., Mackness B., Durrington P.N., Connelly P.W., Hegele R.A. (1996) Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol;7:69-76.
43. Aviram M., Billecke S., Sorenson R., Bisgaier C., Newton R., Rosenblat M., Erogul J., Hsu C., Dunlop C., La Du B. (1998) Paraoxonase active site required for protection against LDL oxidation involves its free sulphydryl group and is different from that required for its arylesterase/paraoxonase activities selective active of human paraoxonase alloenzymes Q and R. Arterioscler Thromb;18:1617-1624.
44. Ekinci D., Beydemir S., Kufrevioglu O.I. (2007) In vitro inhibitory effects of some heavy metals on human erythrocyte carbonic anhydrases. J Enzyme Inhib Med Chem;22:745-750.
45. Robertson J.G. (2007) Enzymes as a special class of therapeutic target: clinical drugs and modes of action. Curr Opin Struct Biol;17:674-679.
46. Abdollahi M., Jafari A., Jalali N., Balali-Mood B., Kebriaeezadeh A., Nikfar S. (1995) A new approach to the efficacy of oximes in the management of acute organophosphate poisoning. Iranian J Med Sci;20:105-109.
47. Shadnia S., Azizi E., Hosseini R., Khoei S., Fouladdel S., Pajoumand A., Jalali N., Abdollahi M. (2005) Evaluation of oxidative stress and genotoxicity in organophosphorus insecticide formulators. Hum Exp Toxicol;9:439-445.
48. Ashani Y., Pistinner S. (2004) Estimation of the upper limit of human butyrylcholinesterase dose required for protection against organophosphates toxicity: a mathematically based toxicokinetic model. Toxicol Sci;77:358-367.
49. Akgur S.A., Ozturk P., Solak I., Moral A.R., Ege B. (2003) Human serum paraoxonase (PON1) activity in acute organophosphorus insecticide poisoning. Forensic Sci Int;133:136-140.
50. Coban T.A., Beydemir S., Gulcin I., Ekinci D. (2008) The inhibitory effect of ethanol on Carbonic Anhydrase isoenzymes: An in vivo and in vitro study. J Enzyme Inhib Med Chem;23:266-270.
51. Ekinci D., Beydemir S., Alim Z. (2007) Some drugs inhibit in vitro hydratase and esterase activities of human carbonic anhydrase-I and II. Pharmacol Rep;59:580-587.
52. Gulcin I., Beydemir S., Coban A., Ekinci D. (2008) The inhibitory effect of dantrolene sodium and propofol on 6-phosphogluconate dehydrogenase from rat erythrocyte. Fresen Environ Bull;17:1283-1287.
53. Tomás M., Senti M., Garcia-Faria F., Vila J., Torrents A., Covas M., Marrugat J. (2000) Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler Thromb;20:2113-2119.